Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187928 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder
A Phase 3 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT00187928 is a Phase 3 study that has completed, run by University of Florida. The registered enrollment target is 96 participants.
The verdict
NCT00187928, a Phase 3 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is an investigational drug for OCD, which means it has not been approved by the U.S. Food and Drug Administration (FDA). Topiramate has been approved as an add-on therapy for adults and children with partial onset seizures or generalized tonic-clonic seizures, and for patients 2 years of age and older with a severe form of epilepsy called Lennox-Gastaut Syndrome. Up to 96 subjects will be enrolled in this study. This study consists of three phases: Washout/Screening Phase, Double-Blind Phase, and Taper Phase. The total expected length of your participation in the study is approximately four months.
Interventions
- DRUG Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2003-01 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187928
The ClinicalTrials.gov registry entry for NCT00187928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topiramate is the first listed.
NCT00187928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187928 about?
NCT00187928 is a clinical study titled "Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder". The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder (OCD). Topiramate is an investigational drug for OCD, which means it has not been approved by the U.S. Food and Drug Administration (FDA)...
What is the current status of trial NCT00187928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2003-01. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00187928?
The interventions under investigation include: Topiramate (DRUG).
Who is sponsoring clinical trial NCT00187928?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.